Chronic Obstructive Pulmonary Disease | Disease Landscape and Forecast | G7 | 2018
MARKET OUTLOOK
The COPD market is continuing its gradual shift away from LABA/ICSFDCs toward LABA/LAMA FDCs, but current and emerging generics will have a significant impact on this trend. Some branded-generic and generic LABA/ICSFDCs have already launched in the United States and Europe, and more will reach the market in the United States in the near future; given that cost remains a significant driver, competition from these generics is expected to impact uptake of both LABA/LAMAs and emerging LABA/LAMA/ICSFDCs. Physicians are eager to have alternative treatments for this chronic disease as development of novel drug classes continues in COPD.
QUESTIONS ANSWERED
- How will markets react to the launch of generic LABA/ICSFDCs and tiotropium? Will there be significant country-to-country differences in uptake of these generics?
- Will LABA/LAMAFDCs continue to gain market share, or will generic therapies or branded LABA/LAMA/ICSFDCs threaten these agents?
- What proportion of patients currently receive a combination of two or more therapies in separate inhalers? How many receive triple therapy, and will these patients be shifted to FDCs?
- Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
